Emphysema is a type of Chronic Obstructive Pulmonary Disease (COPD) and a major cause of death. Studies suggest that emphysema is more common in HIV positive people (HIV+) compared to HIV negative (HIV-) people. The purpose of this research study is to determine whether emphysema in HIV+ patients is clinically and biologically different compared to emphysema in those without HIV.
This study will measure biomarkers in order to monitor and predict health states of disease progression in subjects with Idiopathic Pulmonary Fibrosis (IPF) over 5 years.
The study will consist of a naive (drug free) cohort if subjects have not already been on pirfenidone or nintedanib. Once in the open-label treatment group, subjects will be on either pirfenidone or nintedanib. Subjects will be asked to have blood drawn at their standard of care visits with the option of volunteering for two additional sub-studies.